23-04-2024 | Hepatic Encephalopathy | Original Article
A Prospective Multimodal Education Intervention for Providers Does Not Increase Hepatic Encephalopathy Treatment Rates
Authors:
Patrick A. Twohig, Thoetchai Bee Peeraphatdit, Kaeli Samson, Makayla Schissel, Lynette Smith, Allison Ashford, Laura Freese, Timothy McCashland
Published in:
Digestive Diseases and Sciences
Login to get access
Abstract
Background
Over 50% of hospitalizations from hepatic encephalopathy (HE) are preventable, but patients often do not receive medical treatment.
Aims
To use a multimodal education intervention (MMEI) to increase HE treatment rates and to evaluate (1) trends in HE treatment, (2) predictors of receiving treatment, and (3) the impact of treatment on hospitalization outcomes.
Methods
Prospective single-center cohort study of patients hospitalized with HE from April 1, 2020–September 30, 2022. The first 15 months were a control (“pre-MMEI”), the subsequent 15 months (MMEI) included three phases: (1) prior authorization resources, (2) electronic order set, and (3) in-person provider education. Treatment included receiving any drug (lactulose or rifaximin), or combination therapy. Treatment rates pre- vs. post-MMEI were compared using logistic regression.
Results
471 patients were included. There were lower odds of receiving any drug post-MMEI (p = 0.03). There was no difference in receiving combination therapy pre- or post-MMEI (p = 0.32). Predictors of receiving any drug included alcohol-related or cryptogenic cirrhosis (p’s < 0.001), and the presence of ascites (p = 0.005) and/or portal hypertension (p = 0.003). The only significant predictor of not receiving any drug treatment was having autoimmune cirrhosis (p < 0.001). Patients seen by internal medicine (p = 0.01) or who were intoxicated (p = 0.02) were less likely to receive rifaximin. Any treatment was associated with higher 30-day liver disease-specific readmission (p < 0.001).
Conclusion
This MMEI did not increase HE treatment rates, suggesting that alternative strategies are needed to identify and address barriers to treatment.